Infections caused by rare mold fungi in hematology

Worldwide distribution of mold fungi and their extremely danger for immune compromise patients makes this issue one of the unsolved problems in modern oncology. Three cases of rare fungal infections in children with hematological malignancies are described. In the first case infection caused by Acremonium spp. in AML patients was controlled after voriconazole therapy and granulocytes recovery. The second patients with aplastic anemia died as a result of invasive fungal infection caused by Fusarium spp. despite of combined antifungal therapy and granulocytes transfusions. In the third case diagnosis of Mucor mycosis was made only at autopsy

1. Groll A.H., Lehrnbecher T. New antifungal drugs and the pediatric cancer patient: current status of clinical development. Klin Padiatr 2005;217(3): 158–68.

2. Groll A.H., Walsh T.J. Fungal infections in the pediatric patient. In: Anaissie E., McGinnis M., Pfaller M., eds. Clinical mycology. 1-st ed. N.Y.: Churchill Livingstone, 2003. Рp. 417–42.

3. Marr K.A., Carter R.A., Crippa F. et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909–17.

4. Pagano L., Caira M., Candoni A. et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068–75.

5. Kontoyiannis D.P., Wessel V.C., Bodey G.P. et al. Zigomycosis in the 1990-s in a tertiary – care cancer center. Clin Infect Dis 2000;30:851–6.

6. Musa M.O., Al Eisa A., Halim M. et al. The spectrum of Fusarium infection in immunocompromized patients with haemotological malignancies and in nonimmunocompromized patients: a single institution experience over 10 years. Br J Haematol 2000;108:544–8.

7. Nenoff P., Kelermann S., Schober R. et al. Rhinocerebral zygomycosis following BMT in chronic myelogenous leukemia. Report of a case and review of the literature. Mycoses 1998;41:365–72.

8. Gonzales C.E., Couriel D.R., Walsh T.J. Disseminated zygomycosis in a neutropenic patient: successful treatment with mphotericin B lipid complex and granulocyte colonystimulating factor. Clin Infect Dis 1997;24:192–6.

9. Singh N., Aguado J.M., Bonatti H. et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case- control study to assess risk for disease and outcome. J Infec Dis 2009;200(6): 1002–11.

10. Fincher R.M., Fisher J.F., Lovell R.D. et al. Infection due to the fungus Acremonium (Cephalosporium). Medicine (Baltimore) 1991;70:398–409.

11. Schell W.A., Perfect J.R. Fatal, disseminated Acremonium strictum infection in a neutropenic host. J Clin Microbiol 1996;34:1333–6.

12. Roilides E., Bibashi E., Acritidou E. et al. Acremonium fungemia in two immunocompromised children. Pediatr Infect Dis J 1995;14:548–50.

13. Raad I., Tarrand J., Hanna H. et al. Epidemiology, molecular mycology and invironmental sources of Fusarium infection in patients with cancer. Infect Control Hosp Epidemial 2002;23:532–7.

14. Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood 1997;90:999–1008.

15. Gonzales C.E., Rinaldi M.G., Sugar A.M. Zygomycosis. Infect Dis Clin 2002;16:895–914.

16. Caillot D., Mannone L., Cuisenier B., Couaillier J.F. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect 2001;7 Suppl 2:54–61.

17. Liles W.C., Huang J.E., Van Burik J.A. et al. Granulocyte colony-stimulating factor administered in vivo augments neutrophilmediated activity against opportunistic fungal pathogens. J Infect Dis 1997;175:1012–5.

18. Sahin B., Paydas S., Cosar E. et al. Role of granulocyte colony-stimulating factor in the treatment of mucormycosis. Eur J Clin Microbiol Infect Dis 1996;15:866–9.

19. Bodey G.P., Anaissie E., Gutterman J. et al. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993;17:705–7.

20. Tedder M., Spratt J.A., Anstadt M.P. et al. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994;57:1044–50.

21. Walsh T.J., Hiemennz J.W., Seibel N.L. et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383–96.

22. Alexander B., Perfect J., Daly J. et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008;86:791–6.

23. Peel T., Daffy J., Thursky K. et al. Posaconazole as first line treatment for disseminated zygomycosis. Mycoses 2008;51:542–5.

24. Walsh T.J., Kontoyiannis D.P. What is the role of combination therapy in management of zygomycosis? Clin Infect Dis 2008;47:372–4.